ROVI has commenced the marketing of its enoxaparin biosimilar in Spain


No votes yet
 
Related
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the conclusion of the PRISMA-3 and BORIS  studies, thus...
5 min
05/07/2019
The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in...
1 min
27/05/2019
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 8% to 82.2 million euros in the first quarter of 2019, mainly driven...
5 min
08/05/2019